Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).
Bradley SM, Chan PS, Hartigan PM, Nallamothu BK, Weintraub WS, Sedlis SP, Dada M, Maron DJ, Kostuk WJ, Berman DS, Teo KK, Mancini GB, Boden WE, Spertus JA. Bradley SM, et al. Among authors: teo kk. Am J Cardiol. 2015 Jul 15;116(2):167-73. doi: 10.1016/j.amjcard.2015.03.057. Epub 2015 Apr 17. Am J Cardiol. 2015. PMID: 25960375 Free PMC article. Clinical Trial.
Effect of serum lipid concentrations on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dl and triglycerides < 350 mg/dl.
Dzavik V, Teo KK, Yokoyama S, Modi R, Dinwoodie A, Burton JR, Tymchak WJ, Montague TJ. Dzavik V, et al. Among authors: teo kk. Am J Cardiol. 1995 May 1;75(14):936-8. doi: 10.1016/s0002-9149(99)80691-2. Am J Cardiol. 1995. PMID: 7733005 Clinical Trial. No abstract available.
Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]--a pilot study).
Dzavik V, Beanlands DS, Davies RF, Leddy D, Marquis JF, Teo KK, Ruddy TD, Burton JR, Humen DP. Dzavik V, et al. Among authors: teo kk. Am J Cardiol. 1994 May 1;73(12):856-61. doi: 10.1016/0002-9149(94)90809-5. Am J Cardiol. 1994. PMID: 8184807 Clinical Trial.
Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA).
Dzavik V, Carere RG, Mancini GB, Cohen EA, Catellier D, Anderson TE, Barbeau G, Lazzam C, Title LM, Berger PB, Labinaz M, Teo KK, Buller CE; Total Occlusion Study of Canada Investigators. Dzavik V, et al. Among authors: teo kk. Am Heart J. 2001 Aug;142(2):301-8. doi: 10.1067/mhj.2001.116960. Am Heart J. 2001. PMID: 11479470 Clinical Trial.
Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA).
Yee KM, Buller CE, Catellier D, Cohen EA, Carere RC, Anderson T, Berger P, Burton JR, Barbeau G, Teo KK, Dzavik V; Total Occlusion Study of Canada (TOSCA) Investigators. Yee KM, et al. Among authors: teo kk. Catheter Cardiovasc Interv. 2005 Oct;66(2):178-84. doi: 10.1002/ccd.20410. Catheter Cardiovasc Interv. 2005. PMID: 15977265 Clinical Trial.
Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424.
Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS; COURAGE trial coprincipal investigators and study coordinators. Boden WE, et al. Among authors: teo kk. Am Heart J. 2006 Jun;151(6):1173-9. doi: 10.1016/j.ahj.2005.08.015. Am Heart J. 2006. PMID: 16781214
The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
Boden WE, O'rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Gau G, Weintraub WS; COURAGE Trial Co-Principal Investigators and Study Coordinators. Boden WE, et al. Among authors: teo kk. Am J Cardiol. 2007 Jan 15;99(2):208-12. doi: 10.1016/j.amjcard.2006.07.082. Epub 2006 Nov 17. Am J Cardiol. 2007. PMID: 17223420 Clinical Trial.
Optimal medical therapy with or without PCI for stable coronary disease.
Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Boden WE, et al. Among authors: teo kk. N Engl J Med. 2007 Apr 12;356(15):1503-16. doi: 10.1056/NEJMoa070829. Epub 2007 Mar 26. N Engl J Med. 2007. PMID: 17387127 Free article. Clinical Trial.
337 results